Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)

Observational Study in Patients With Functional BPH (Benign Prostatic Hyperplasia) Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)

The objective of the observational study were to investigate the switch from phytotherapy to ALNA® after at least 4 weeks of phytotherapy and still presented with a symptom sum score of ≥ 8 points (International Prostate Symptom Score (IPSS))

Inclusion Criteria:

• Patients suffering from BPH symptoms
• Preceding treatment with a phytotherapeutic for at least 4 weeks
• IPSS sum score ≥ 8 points prior to treatment start with ALNA®
• Indication for a switch to treatment with ALNA® for a minimum period of 2 months

Exclusion Criteria:

• Patients fulfilling one of the general or specific contraindications listed in the ALNA® Summary of Product Characteristic, particularly patients with known hypersensitivities against tamsulosin hydrochloride or any other ingredient of the product, orthostatic dysregulation or severe liver insufficiency
• Patients receiving ALNA® within the 4 weeks prior to the start of the present observational study